Method and device of treating chronic kidney disease-associated pruritus

Transmucosal nalmefene administration via a mucoadhesive film addresses the lack of effective treatments for chronic kidney disease-associated pruritus by targeting Substance P, offering rapid and effective relief.

US12642796B2Active Publication Date: 2026-06-02AVIOR BIO INC
View PDF 42 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Patents(United States)
Current Assignee / Owner
Filing Date
2019-10-17
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

There are no approved products in the United States to treat chronic kidney disease-associated pruritus, cholestatic pruritus, or prurigo nodularis, and current treatments like corticosteroids and antihistamines are ineffective for moderate to severe forms, affecting approximately 18% of patients.

Method used

Transmucosal administration of nalmefene or its pharmaceutically acceptable salts, specifically through buccal or sublingual routes, using a single-layer mucoadhesive film with distinct domains for enhanced absorption and permeation, targeting Substance P to mitigate pruritus.

Benefits of technology

The method effectively reduces Substance P levels, providing relief from chronic kidney disease-associated pruritus, cholestatic pruritus, and prurigo nodularis by achieving rapid absorption and therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US12642796-D00001
    Figure US12642796-D00001
  • Figure US12642796-D00002
    Figure US12642796-D00002
  • Figure US12642796-D00003
    Figure US12642796-D00003
Patent Text Reader

Abstract

The presently disclosed subject matter is directed to an effective method of treating chronic kidney disease-associated pruritus. Particularly, the method comprises the transmucosal administering of nalmefene to treat chronic kidney disease-associated pruritus, as well as cholestatic pruritus and / or prurigo nodularis. The nalmefene can be configured in a single layer film comprising at least two distinct domains. The film can include a first discrete domain comprising about 50-100 weight percent polymer matrix and the second discrete domain can comprise the nalmefene or pharmaceutically acceptable nalmefene salt.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Active substance carrier for releasing apomorphine into the buccal cavity

    CA2274893A1

  • A preparation for use in the buccal cavity having a layer which is pressure-sensitive to the mucosa and contains pharmaceuticals or cosmetics for metered release

    DE19646392A1

  • Method and apparatus for minimising heat, moisture and shear damage to drugs and other compositions

    EP1462095A1

  • Quickly soluble filmy preparation

    JP2004043450A

  • Transmucosal film composition and methods of making and using the same.

    MX2020008694A